RWM
DNLI icon

Raffa Wealth Management’s Denali Therapeutics DNLI Stock Holding History

Raffa Wealth Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26 Hold
1
– – ﹤0.01% 1562
2026
Q1 		$19 Buy
+1
New +$20 ﹤0.01% 1483
2021
Q2 		– Sell
-1
Closed -$57 – 1101
2021
Q1 		$57 Hold
1
– – ﹤0.01% 1098
2020
Q4 		$84 Buy
+1
New +$60 ﹤0.01% 909

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Raffa Wealth Management's DNLI Position: Q2 2026 in Review

Raffa Wealth Management held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 1 share worth $26. The position accounts for ﹤0.01% of the portfolio, ranked #1562.

Raffa Wealth Management first reported a position in DNLI in Q4 2020 and has held it in 4 quarters since. The position peaked at $84 in Q4 2020. 273 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Raffa Wealth Management held 1 share of Denali Therapeutics worth $26 as of Q2 2026.
  • Raffa Wealth Management left its Denali Therapeutics share count unchanged in Q2 2026.
  • Denali Therapeutics made up ﹤0.01% of Raffa Wealth Management's portfolio in Q2 2026, its #1562 holding.
  • Raffa Wealth Management first reported a position in Denali Therapeutics in Q4 2020 and has held it in 4 quarters since.
  • Raffa Wealth Management's Denali Therapeutics position peaked at $84 in Q4 2020.
  • 273 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Raffa Wealth Management's 13F filing for Q2 2026, filed 27 Jul 2026.